Amarin Co. plc (NASDAQ:AMRN) Director Lars Ekman sold 91,016 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $15.01, for a total transaction of $1,366,150.16. Following the transaction, the director now directly owns 13,500 shares in the company, valued at approximately $202,635. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of NASDAQ:AMRN traded up $0.27 during trading hours on Friday, hitting $16.27. 5,341,623 shares of the company’s stock traded hands, compared to its average volume of 8,205,606. Amarin Co. plc has a 52 week low of $2.65 and a 52 week high of $23.91. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.76 and a current ratio of 2.01. The company’s fifty day simple moving average is $16.26 and its two-hundred day simple moving average is $18.46. The company has a market cap of $5.72 billion, a price-to-earnings ratio of -41.72 and a beta of 1.27.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. The company had revenue of $100.40 million during the quarter, compared to analyst estimates of $99.54 million. During the same quarter last year, the firm posted ($0.10) EPS. The business’s revenue for the quarter was up 90.9% on a year-over-year basis. On average, analysts anticipate that Amarin Co. plc will post -0.2 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. boosted its holdings in shares of Amarin by 1,402.6% in the second quarter. Invesco Ltd. now owns 8,414,943 shares of the biopharmaceutical company’s stock worth $163,166,000 after buying an additional 7,854,902 shares during the period. Farallon Capital Management LLC boosted its holdings in shares of Amarin by 30.8% in the second quarter. Farallon Capital Management LLC now owns 4,250,000 shares of the biopharmaceutical company’s stock worth $82,408,000 after buying an additional 1,000,000 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Amarin by 67.2% in the first quarter. Rubric Capital Management LP now owns 2,250,000 shares of the biopharmaceutical company’s stock worth $46,710,000 after buying an additional 904,624 shares during the period. EULAV Asset Management boosted its holdings in shares of Amarin by 12.3% in the second quarter. EULAV Asset Management now owns 1,740,000 shares of the biopharmaceutical company’s stock worth $33,739,000 after buying an additional 190,000 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of Amarin by 28.9% in the second quarter. Morgan Stanley now owns 1,639,098 shares of the biopharmaceutical company’s stock worth $31,782,000 after buying an additional 367,369 shares during the period. Institutional investors own 44.94% of the company’s stock.

Several research firms have recently weighed in on AMRN. Svb Leerink began coverage on shares of Amarin in a research report on Wednesday, August 14th. They set an “outperform” rating and a $26.00 price objective for the company. Roth Capital set a $31.00 price objective on shares of Amarin and gave the company a “buy” rating in a research report on Wednesday, August 21st. Leerink Swann began coverage on shares of Amarin in a research report on Wednesday, August 14th. They set an “outperform” rating for the company. Zacks Investment Research lowered shares of Amarin from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Finally, Cantor Fitzgerald set a $35.00 price objective on shares of Amarin and gave the company a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $29.89.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Featured Article: How does a margin account work?

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.